Literature DB >> 11583755

MHC class II region, CTLA4 gene, and ophthalmopathy in patients with Graves' disease.

A Allahabadia, J M Heward, R Nithiyananthan, S M Gibson, T T Reuser, P M Dodson, J A Franklyn, S C Gough.   

Abstract

Up to half of patients with Graves' hyperthyroidism have signs of thyroid associated ophthalmopathy, but the factors that cause this disorder are unknown. We investigated two major genetic susceptibility loci for Graves' disease in ophthalmopathy; the MHC class II region and the cytotoxic T lymphocyte antigen-4 (CTLA4) gene. Allelic frequencies of these genes in patients with Graves' disease who did and did not have concurrent thyroid-associated ophthalmopathy did not differ, and are, therefore, unlikely to contribute to its development.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11583755     DOI: 10.1016/s0140-6736(01)06125-6

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  15 in total

1.  Genetic profiling in Graves' disease: further evidence for lack of a distinct genetic contribution to Graves' ophthalmopathy.

Authors:  Xiaoming Yin; Rauf Latif; Rebecca Bahn; Terry F Davies
Journal:  Thyroid       Date:  2012-06-04       Impact factor: 6.568

Review 2.  [Endocrine orbit disorders. Pathogenesis, clinical presentation and examination, stage-dependent therapy].

Authors:  A Eckstein; J Esser
Journal:  Ophthalmologe       Date:  2003-10       Impact factor: 1.059

3.  Association of BTG2, CYR61, ZFP36, and SCD gene polymorphisms with Graves' disease and ophthalmopathy.

Authors:  Tereza Planck; Bushra Shahida; Marketa Sjögren; Leif Groop; Bengt Hallengren; Mikael Lantz
Journal:  Thyroid       Date:  2014-06-03       Impact factor: 6.568

4.  Association of Graves' disease and Graves' ophthalmopathy with the polymorphisms in promoter and exon 1 of cytotoxic T lymphocyte associated antigen-4 gene.

Authors:  Qin Zhang; Yun-mei Yang; Xue-ying Lv
Journal:  J Zhejiang Univ Sci B       Date:  2006-11       Impact factor: 3.066

Review 5.  Risk factors for development or deterioration of Graves' ophthalmopathy.

Authors:  Marius N Stan; Rebecca S Bahn
Journal:  Thyroid       Date:  2010-07       Impact factor: 6.568

6.  TSHR intronic polymorphisms (rs179247 and rs12885526) and their role in the susceptibility of the Brazilian population to Graves' disease and Graves' ophthalmopathy.

Authors:  N E Bufalo; R B Dos Santos; M A Marcello; R P Piai; R Secolin; J H Romaldini; L S Ward
Journal:  J Endocrinol Invest       Date:  2014-12-28       Impact factor: 4.256

Review 7.  The CD40, CTLA-4, thyroglobulin, TSH receptor, and PTPN22 gene quintet and its contribution to thyroid autoimmunity: back to the future.

Authors:  Eric M Jacobson; Yaron Tomer
Journal:  J Autoimmun       Date:  2007-03-21       Impact factor: 7.094

Review 8.  Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints.

Authors:  Lee-Shing Chang; Romualdo Barroso-Sousa; Sara M Tolaney; F Stephen Hodi; Ursula B Kaiser; Le Min
Journal:  Endocr Rev       Date:  2019-02-01       Impact factor: 19.871

Review 9.  Unravelling the genetic complexity of autoimmune thyroid disease: HLA, CTLA-4 and beyond.

Authors:  M J Simmonds; S C L Gough
Journal:  Clin Exp Immunol       Date:  2004-04       Impact factor: 4.330

10.  Association between the CTLA-4 +49A/G polymorphism and Graves' disease: A meta-analysis.

Authors:  Xiaoyu Si; Xiufeng Zhang; Wenru Tang; Ying Luo
Journal:  Exp Ther Med       Date:  2012-06-20       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.